Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

NCT00608231
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia
Interventions
Dexmedetomidine Hydrochloride Infusion, Normal Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

Multi-site Adaptive Trials for COVID-19

NCT04370262
View directory record Official record
Conditions
COVID-19
Interventions
SOC + Intravenous Famotidine, SOC + Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 17, 2026, 4:41 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Vasodilators and Anti-Oxidant Therapy in Early ATN

NCT00286403
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Fenoldopam Mesylate and/or MESNA
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 17, 2026, 4:41 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Ciprofloxacin in Humans

NCT00964561
View directory record Official record
Conditions
Anthrax
Interventions
Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug · Other
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03636269
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

NCT05386823
View directory record Official record
Conditions
Healthy
Interventions
HF1K16, Placebo
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

NCT01166542
View directory record Official record
Conditions
Carcinoma, Squamous Cell of the Head and Neck
Interventions
REOLYSIN, Carboplatin, Paclitaxel, Placebo
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • Burbank, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00095173
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
10
States / cities
Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Not applicable Interventional

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

NCT00001123
View directory record Official record
Conditions
Hantavirus Pulmonary Syndrome
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861
View directory record Official record
Conditions
Safety Issues
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

NCT05305222
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Study to Evaluate SYN115 in Parkinson's Disease

NCT00605553
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, Tozadenant
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of VLX-1005 in Healthy Subjects

NCT04783545
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
VLX-1005, Placebo
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
19 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

NCT00078611
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
63
States / cities
Oro Valley, Arizona • Tucson, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 17, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
48
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 17, 2026, 4:41 AM EDT
Not yet recruiting Early Phase 1 Interventional

Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings

NCT07348172
View directory record Official record
Conditions
Drug Liking
Interventions
Amisulpride, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

NCT01273467
View directory record Official record
Conditions
Stroke, Ischemia, Infarction
Interventions
CNTO 0007 or placebo (Stage A), CNTO 0007 or placebo (Stage B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI

NCT04671030
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Neurogenic Bowel
Interventions
Neostigmine and Glycopyrrolate, Iontophoresis
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

NCT01300728
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

NCT00247572
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

NCT03585257
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions
25% IV albumin, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

NCT00002244
View directory record Official record
Conditions
HIV Infections
Interventions
WF10
Drug
Lead sponsor
OXO Chemie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

NCT02920021
View directory record Official record
Conditions
Peanut Allergy
Interventions
Etokimab, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 17, 2026, 4:41 AM EDT